Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
With the market hammering us today it looks like those two jumped from our sinking ship. They obviously know more about what is going on at Aurinia. What a cluster this is.
Because they were the architects of the failed patent strategy
If it was so clear that that is the case, you would think the market would recognize that as well and be driving the stock higher not lower.
not a bad gig if you can get a 6 figure vacation package.
amazing the amount of shareholder funds they can just give at a termination of employment in a company that is anything but self supporting.
let me add, you all sound like a bunch of whiney kids today.
peter could have taken bmy's bo offer that most likely would have been above the 34.00 stock price at the time. Yet we sit here just above 7.00.
peters arrogance that he thinks he can go this alone is obviously proven in the current share price.
The market may see the value of the product, but with the captain of the titanic
steering the ship, all they see is not enough life boats and life preservers.
There is nothing better than the consensus of individuals on a message board to power the stock higher….
I think Cervelo will love statement about Peter
I agree with Ganz and Greggors 101%.
Ganz, are you also an author that is well known for writing incredible quality fiction??
…..Im guessing it probably went something like this:
Neil and Robert - “ we want massive salaries, pensions, stock options abound and free reign to come and go as we please”!
Potential suitor “ No”
Neil and Robert- “ Peter let us do whatever we wanted and gave us insurmountable amounts of cash, ridiculously lucrative stock options and autonomy to run the show”
Potential suitor “ that's why AUPH’s stock value has plummeted “
Neil and Robert “ if you don’t honor our demands, we’re outta here”!
Potential Suitor “ bye bye
“These are the two most likely peeps to go in a BO.
The likes of a GSK or BMY would have no use for these dudes and their massive salaries when they already have their own.”
Ganz, I’m surprised by your statement and thinking. Executive VP and CMO would have glorious golden parachutes in any buyout. You don’t force them out in just a few weeks. It just doesn’t work that way..
“They had to have been made redundant for some reason, BMY probably has their own VP of R&D.”
LOL!
These are the two most likely peeps to go in a BO.
The likes of a GSK or BMY would have no use for these dudes and their massive salaries when they already have their own.
They had to have been made redundant for some reason, BMY probably has their own VP of R&D.
Huizenga is only there for 4 but Solomons is12.
with no follow through today, at least right now it makes yesterdays move a little head scratchjing
This absolutely sucks:
Departure of Executive Vice President, Research and Chief Medical Officer
On October 17, 2022, Aurinia Pharmaceuticals Inc. and Robert Huizinga, PhD RN, CNeph(C), our Executive Vice President, Research and Neil Solomons, M.D., our Chief Medical Officer, mutually agreed that Dr. Huizinga and Dr. Solomons would cease their employment with Aurinia, each effective October 31, 2022.
This would never happen in a buyout. These were KEY employees who have been with the company for many, many years..
I know the future is down right this hour but if the action today is the same as yesterday, then something is in the offing.
Could be a merger…
The company and those individuals agreed on the 17th, but the 8K is dated Oct. 21, yesterday. So news not released until yesterday - but obviously some knew.
First thought was that maybe they were clearing the decks for a BO but I think I am reaching with that. Maybe the price shot up yesterday as some heard that there was going to be news but they didn't exactly know what it was going to be and of course some shorts may have wanted to not get caught.
The question remains though, why would two people in very prominent and important positions be let go?
How can two resignations of two executives with prominent roles in the organization be bullish. Yesterday’s action was a little bullish and then a PR like this? Boy, we just can’t get a break from these doldrums.
Thanks for posting
So this was announced on Monday. From the PPS movement from then what to make of it?
GLTA
Is that a little light at the end of this very long tunnel? There's always hope and days like yesterday help sustain it.
Yes, the more than double the average volume has me hoping it is something of substance causing the move today.
I want to believe there is something behind this sudden uptic crossing the 50day on double the volume, but you never know it could be just algos. AUPH has not mentioned if they are attending the ASG in November 3rd to 6th in Orlando FLA j
Sure, it could be options related manipulation or some development that of course we peons are last to hear about. Patent suit settlement, or another BO rumor about to be released, who knows. Guess we wait to find out.
But the good news is we broke above previous resistance levels. Also Q3 is right around the corner, with some good numbers this can really move.
that makes sense since there was no news.
Sadly it is most likely manipulation by market makers as options expire tomorrow. They sell naked options, in order to make the maximum amount they push the price in the direction they need.
Saud, I think we’ll see a steady uptick with Q3 earnings on the 1st of November
yeah but its higher than the last couple of weeks, we 've reached the daily average with 4 more hours to go!
No but up over 11% now and still no high volume.
does anyone know why we are up 10 per cent today? it is certainly a pleasant surprise.
big move up or down coming... in a downtrend for a year now. The trend is not my friend. Need good Q3 numbers to reverse the trend.
Not one to use technical analysis much, but the Bollinger Bands on AUPH are as tight as a Megaship going through the Panama Canal.
Yes , we do and you know what that is, no need to elaborate.
Jess, my hunch is you and Cervelo have a lot in common…….
and look at him stay around. Wow, can’t figure it out.
and look at her run.
On the daily chart, the hammer candlestick on 9/8 could be the bottom. We have another hammer candlestick on 9/23 with a higher low. Todays close was great, if we can stay above this and breakthrough the $8 resistance we could be on our way up. This is definitely not financial advice, it is TA bullsh*t lol
The script count is completely inaccurate and we will only know when announced. Last Q with revs at $28M was not bad. But the EU approval payout will bump up rev for Q3. Even a flat quarter of sales we still will report around $55M. It will bring a lot more investors that just look at numbers. A blowout Q of $68M is possible IMO.
$MYOV Sweet sweet redemption. I hope many of my $AUPH friends made the move to MYOV a couple months ago. I think final price tag will be north of $30. Still holding full position. https://t.co/KCkaWTo2tG
— JG (@BioLunacyJG) October 5, 2022
Cosa, when you say you are looking forward to the ER, is it because you have been seeing rising scripts? Or some other reason?
Looking forward to the ER next month. Hoping we will push to over $10. Might not be for long as a lot of people are probably going to make an exit.
More free options. Not sure who it went to, nothing on SEC website yet.
Not sure why October $9 strike volume is so heavy. I think that's going to go to $0
Does anyone know how long it typically takes for PATB to respond to appeals? AUPH filed the appeal on August 9th as the per the link below. Checking online, I see conflicting information with regards to response time lasting from 2 months to 15 months.
https://s3-us-west-1.amazonaws.com/ptab-filings%2FIPR2022-00617%2F12
Candidate & Indication | Development Stage | ||||
---|---|---|---|---|---|
Preclinical | Phase 1 | Phase 2 | Phase 3 | Market | |
VOCLOSPORINLupus Nephritis (LN) | Preclinical Phase complete | Phase 1 Phase complete | Phase 2 Phase in progress | Phase 3 Phase not started | Market Phase not started |
Aurinia is committed to working in areas of high unmet medical need and is poised to deliver the first approved therapy in the U.S. and Europe for the treatment of lupus nephritis, or LN.
Voclosporin, an investigational drug, is a novel and potentially best-in-class calcineurin inhibitor (“CNI”) with clinical data in over 2,000 patients across indications. Voclosporin is an immunosuppressant, with a synergistic and dual mechanism of action that has the potential to improve near- and long-term outcomes in lupus nephritis (LN) when added to standard of care mycophenolate mofetil (MMF). It has been granted “fast track status” by the U.S. Food & Drug Administration (FDA).
Voclosporin has the potential to become a best in class medication and the first approved treatment for LN in the U.S. and Europe, effectively altering the current treatment paradigm for the disease.
Our clinical data suggests that adding voclosporin to the current SoC of MMF for the treatment of lupus nephritis (LN) will yield superior results to using the standard of care alone.
Additionally, voclosporin may prove to be an ideal therapy for lupus nephritis due to advantages such as:
In clinical trials, Voclosporin has been shown to be especially effective in the presence of low dose steroids with rapid reduction of LN inflammatory markers and overall improved renal stability.
The list of potential product benefits includes:
LN Critical Need | Voclosporin (based on AURA Results) | |
---|---|---|
Control of Active Disease | ||
Rapid Disease Control | ||
Lower Steroid Burden | ||
Impact on Extra-renal disease | ||
Convenient Treatment Regimen |
In previous studies, over 2000 patients have been treated with Voclosporin with no abnormal or unexpected SAE’s
Efficacy of calcineurin inhibition has already been established. Voclosporin has a well-characterized safety profile (over 2,000 patient exposures across multiple years) across indications.
No new safety signals were observed with the use of Voclosporin in LN patients; Voclosporin was well-tolerated and renal function remained stable in clinical studies. The overall safety profile is consistent with other immunosuppressive drugs.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |